Fig. 5: Sup-tRNA expression level and charging efficiency across various tissues.
From: An engineered UGA suppressor tRNA gene for disease-agnostic AAV delivery
a, Schematics showing the molecular workflow to quantify tRNA level and charging efficiency. The sup-tRNA with the UCA anticodon (blue) and the isodecoders with the CCU anticodon, including the sup-tRNA’s parental isodecoder, can be charged with an amino acid (gray circle) at the CCA at the 3′ terminus or uncharged. b, Bar graph showing the sup-tRNA levels normalized to either its parental isodecoder (left) or total CCT isodecoders (right) across three tissues as indicated. c, Bar graph showing the charging efficiencies of sup-tRNA (blue) and its parental isodecoder across various tissues. d, Bar graph showing the levels of sup-tRNA’s parental isodecoder relative to total CCT isodecoders across various tissues. In b–d, male normal mice at 5–6 weeks of age were treated with MyoAAV.2×CuO-hNFS-R8(VG4) (MyoAAV+) or left untreated (MyoAAV−) and killed 10 weeks later for tissue collection. Each dot represents an individual mouse (n = 3). Data are presented as the mean and s.d. Statistical analysis was performed using a one-way ANOVA followed by Dunnett’s multiple-comparison test in b,c and two-sided t-test in d.
